CorporatePresentationJuly2020

NASDAQ:NMRD

Forward-Looking Statements

•  Thispresentationincludesforward-lookingstatementsthataresubjecttomanyrisksanduncertainties.Theseforward-lookingstatements,suchasstatementsaboutNemaura’sshort-termandlong-termgrowthstrategies,cansometimesbeidentifiedbyuseoftermssuchas“intend,”“expect,”“plan,”“estimate,”“future,”“strive,”andsimilarwords.Thesestatementsinvolvemanyrisksanduncertaintiesthatmaycauseactualresultstodifferfromwhatmaybeexpressedorimpliedinthesestatements.

•  TheserisksarediscussedinNemaura’sfilingswiththeSecuritiesandExchangeCommission(the“Commission”),includingtherisksidentifiedunderthesectioncaptioned“RiskFactors”inNemaura’sAnnualReportonForm10-KfiledwiththeCommissioninJune2019asthesamemaybeupdatedfromtimetotime.

•  Nemauradisclaimsanyobligationtoupdateinformationcontainedintheseforward-lookingstatementswhetherasaresultofnewinformation,futureevents,orotherwise.

2

Our Mission •  Todisruptthe$80B+Diabetes&$50B+Pre-diabetesmarketsbymakingitmucheasierforpeoplewithdiabetesandpre-diabetestomakelifestylechangesneededtomanage,reverseorpreventdiabetes.

•  WeachievethisbycombiningdigitalcoachingandsupportservicesprovidedbyBEAT™diabeteswithcontinuousglucosemeasurements(CGM)&dailyglucosetrenddataprovidedbySugarBEAT®,theworld’sfirstCEMarkapprovedNon-invasiveCGM.

•  Within5yearsNemauraaimstoleadinthewearablesmarketandself-managementofmedicalconditionswithourpipelineproductsofsensorsanddigitalhealthcareplatformsusingAI.

•  Employers,healthcareprovidersandinsurersarealreadypayingsubstantialfeestosupportpatientsforthelongterm,usingappsandcoaching,soSugarBEAT®CGMcombinedwithBEAT™diabetesdigitalcoachingarepoisedtodisruptthisspace.

•  https://sugarbeat.com/introducing-sugarbeat/ 3NASDAQ:NMRD

Company Highlights •  World’sfirstnon-invasiveCGM(continuousglucosemonitor)SugarBEAT®,combinedwithdigitalcoachingandsupportservicesprovidedbyBEAT™diabetestargeting$179B+Globalopportunity:

•  Digitalhealthsectorcomprising$69B+Type2diabetesmarket1

•  $50B+Pre-diabetesmarket2

•  Wearablehealth-techsectorcomprising$60B+weightloss&wellnessmarkets3

•  USFDAPMAsubmittedandapprovalandlaunchanticipatedbyearly2021

•  CEMarkApproved;UK&IrelandcommerciallaunchplannedforQ3inUKandGermany,andQ4inUSA(inthewellbeingspacefordiabetesprevention,priortoPMAapprovalbyFDA).

•  Cleancapitalstructure

NASDAQ:NMRD4

1PiperJaffrayCompanyNoteDXCMSep52018 2Assuming50%usageascomparedtotypeIInoninsulinmarket 3JuniperResearchDigitalHealthReportJan142019

The Market

NASDAQ:NMRD5

TAM:TotalAddressableMarket

SugarBEAT® the Product

NASDAQ:NMRD

6

•  CEMarkapprovedClassIIbdevice,adjuncttofingerpricktesting,forusebypersonswithdiabetes

•  Noninvasive–sensorsitsontopofthearm/skin

•  Readingssenttomobilephoneappevery5minutes

•  Intermittentweartime:

wearitwhenyouchoose

•  Lowcost

•  Canbewornbyanyone–fordiabetesmanagement,toaiddiabetespreventionorforWellbeing

How SugarBEAT® Works •  Asmalltransmitterdeviceandanadhesivepatchwithasensorsitsontopoftheskin,typicallyontheupperarm.•  Thesystempainlesslydrawssmallamountsofglucosemoleculesoutoftheinterstitialfluidjustbelowthetoplayerofskinintoachamberwithinthepatch.Doesnotrequireneedlesandsensordoesnotpuncturetheskin.•  Therechargeabletransmittermeasuresglucoselevelswithinthechamber,andtransmitsthisdataeveryfiveminutesviaBluetoothtoamobilephoneapp.•  Usingaproprietaryalgorithm,theappthendisplaysthisdataasglucosevalueonsmartphone/deviceingraphicalformataswellasnumericvalues.https://sugarbeat.com

7NASDAQ:NMRD

BEAT™diabetes Program

8NASDAQ:NMRD

Cardiovascular Risk Monitoring

Blood Glucose Monitoring

Continuous Glucose

Monitoring

Heart Metrics

Diabetes Lifestyle App

Digitally Connected

Online Community

Blood Testing Personalised

Lifestyle Coaching

Commercialization & Sales – UK & Germany •  UK:Productplannedforonlinesaledirecttoconsumer.Drugtarifflistingapplicationinprogressforreimbursement.

•  Germany:Productplannedforonlinesaledirecttoconsumer.Applicationinprogressforreimbursement.

IndependentstudyoutcomesprovidecompellingevidencefortheuseofCGMonnon-consecutivedaysorafewconsecutivedayspermonth,toprovideclinicallysignificantoutcomesinthemanagementand/orreversalofType2diabetes.

sugarBEAT®isideallypositionedtocaterforthismarketoverandabovetheincumbentinvasiveCGMswhichhavewearperiodsofupto14consecutivedayswithassociatedcosts.

ConsequentlyitmaybepossibletoprovideCGMtothemajorityofpersonswithType2diabetesatanaffordablecostpoint.

ThishasthepotentialtochangetheparadigmforthemanagementofType2diabetesonaglobalscale.

NASDAQ:NMRD 9

Commercialization & Sales - USA

•  USA:PMAfiled.

•  LaunchplannedunderthewellbeingcategorytargetedatType2diabeticsaswellasthepre-diabetesmarket(over100millionpotentialuserscombined).

•  Examplesofincumbentsinthespace:

-Omada,Livongo

NASDAQ:NMRD10

Potentially game-changing moment for big data in the health industry •  TheValueofMedicalDataRealtime•  Mobiletechnologyhasbeenoneofthelargestcontributorstobigdataforthepastseveralyears.Proliferationof

mobilephones,theimplementationofapp-enabledsmartphones,andnowthegrowthofthewearabledevicemarketareallcreatingmassivenewdataflowsthatcanbeputtouseforhealthandotherpurposes.

•  Wearablemedicaldevicesarenotnew,buttheyhavelongbeenexpensiveandnotalwaysviableforeverypatientorsubjectofamedicalstudytowear.That’swhythegrowthofthewearablepersonalelectronicdevicemarket–andthelowerpricesthatcomewithahighervolumeofdevicesbeingsold–issuchapotentiallygame-changingmomentforbigdatainthehealthindustry

•  ExtractingpersonaldatafromwearableMedicaldevices:•  PredictiveanalyticsisbasedonlogicthatisdrawnfromthewearableMedicaldevicesusesanalgorithmtoseek

patternsandstructureindataandclusterthemintogroupsorinsights.

•  Improvingefficienciesperpatient’smanagementofhealthcare

•  Accuracyofdiagnosisandtreatmentinpersonalmedicine

•  Increasedinsightstoenhancelifestyle,diabetes,drugmanagementandcohorttreatment

•  DevelopmentofArtificialIntelligenceandintermittenttestingusingSugarBEAT®hasthepotentialtodisruptdiabetesmanagementfromthefollowingperspectives:

•  EmpoweringuserswithinterpretationsofSugarBEAT®data.EmpoweringIndustrysuchasBigPharmatoenhancedrugtreatmentregimensanddeveloppersonalizedtherapy.

•  Seekingtocapitalizeonthisgroundbreakingapproachtomakinglargedatasetsmoreaccessible,theU.S.NationalInstitutesofHealth—thepreeminentU.S.governmentmedicalresearchorganization,whichoverseesanannual$31billionbudget—isnowworkingwithIBMtoconnectaverywidevarietyofclinicalandresearchdatasetstotheIBMWatsonsystem.

NASDAQ:NMRD11SugarBEAT®

Nemaura vs Livongo® The technical difference! Starts with a supporting approved medical device. •  TheTrendsInMobileHealthcare

•  Whatweareseeingisashifttowardsdigitalmedicalcare.Therecordsaremoreoftenkeptelectronically,therearemoreopportunitiesforremotepatientmonitoring,andmoretoolsforindividualhealthmonitoringareemerging.Digitalhealthdealsarebooming:thevalueofinvestmentsreached$7.5billionin20192.

•  Nemauraisthelatestbreakthroughinmobile/wearablehealthcaretechnologyregardingfunctionality,technology,interconnectivityandallsupportedwithrealmedicaldiagnosticsfromtheirCEapprovedmedicaldevice.•  Livongo®Limitations:(NASDAQ:LVGO)

•  Livongo®forDiabetes:includesacellular-connectedinteractiveglucometer,unlimitedbloodglucoseteststrips,real-timecoaching,and24-hourmonitoring

•  LivongoforPre-DiabetesandWeightManagement:offersacellular-connectedweightscale,healtheducationalcontent,personalizedcoachingservice,andgroupclasses

•  NemauraAdvantages:•  SugarBEAT®CGMprovidesverypowerfuldatathatwillallowlongtermtherapyand

lifestyleadjustmentsthatfingerpricktestingcannotachieve

•  Clinicallyproven,evidencebasedhealtheducationondiabetesthathasbeendemonstratedtoleadtobehavioralchangesindiabetics.On-demandcoachingserviceforpersonalfitness,motivation,anddietaryadvice,(throughin-licensingandcollaboration)

NASDAQ:NMRD1.Livongo®isaregisteredtrademarkofLivongoHealth,Inc.

2.https://www.digitalhealth.net/2020/01/ces-2020-digital-health-investment-2019/12

Opportunities for application of big data in the health industry TheValueofMedicalDataRealtime•  Mobiletechnologyhasbeenoneofthelargestcontributorstobigdataforthepastseveralyears.

Proliferationofmobilephones,theimplementationofapp-enabledsmartphones,andnowthegrowthofthewearabledevicemarketareallcreatingmassivenewdataflowsthatcanbeputtouseforhealthandotherpurposes.

•  Wearablemedicaldevicesarenotnew,buttheyhavelongbeenexpensiveandnotalwaysviableforeverypatientorsubjectofamedicalstudytowear.That’swhythegrowthofthewearablepersonalelectronicdevicemarket–andthelowerpricesthatcomewithahighervolumeofdevicesbeingsold–issuchapotentiallygame-changingmomentforbigdatainthehealthindustry

ExtractingpersonaldatafromwearableMedicaldevices:•  PredictiveanalyticsisbasedonlogicthatisdrawnfromthewearableMedicaldevicesusesan

algorithmtoseekpatternsandstructureindataandclusterthemintogroupsorinsights.

•  Improvingefficienciesperpatient’smanagementofhealthcare

•  Accuracyofdiagnosisandtreatmentinpersonalmedicine

•  Increasedinsightstoenhancelifestyle,diabetes,drugmanagementandcohorttreatment

InitialdevelopmentofArtificialIntelligenceandintermittenttestingusingSugarBEAT®hasthepotentialtodisruptdiabetesmanagementfromthefollowingperspectives:•  EmpoweringuserswithinterpretationsofSugarBEAT®data.EmpoweringIndustrysuchasBig

Pharmatoenhancedrugtreatmentregimensanddeveloppersonalizedtherapy.

•  Seekingtocapitalizeonthisapproachtomakinglargedatasetsmoreaccessible,theU.S.NationalInstitutesofHealth—thepreeminentU.S.governmentmedicalresearchorganization,whichoverseesanannual$41.7billionbudget1—isnowworkingwithIBMtoconnectaverywidevarietyofclinicalandresearchdatasetstotheIBMWatsonsystem.

NASDAQ:NMRD

SugarBEAT®

1.https://www.nih.gov/about-nih/what-we-do/budget 13

ThenumberofpeoplethatcouldbenefitfromSugarBEAT®issignificantbuteveninascenariowherethiswasonlyrolledoutacrossstaffconsideredtobehighvalueassetstothe100biggestcompaniesintheUK,weforecastthishavingthepotentialofachievingover200,000subscribersintheUKalone.NHS(UK)DiabetesPreventionProgram(DPP)DigitalStream•  DPPtosupport200,000peopleperyeartotransformtheirlifestyles

•  Fivedigitalbehaviorchangeproviders•  Basedoncontinuousengagementwithpatientstomakenewhabitsandbehaviors

•  Helppatientstoimprovetheirconditionsbypersonalizedhealthlifestyleplansandcoaching

NHS(UK)Type2behaviorchangeatscale•  PartnershipwithNHSEnglandofferingfreedigitalsupportforpeoplediagnosedwithType2diabetes

•  Onlineplatformwilldeliverthisbehaviorchangeservicenationally

•  Evidencebasededucationwithinnovativetechnologytoprovidepersonalizationatscale

SugarBEAT®$179B+GlobalMarketopportunityconsistsofthreetargetmarkets:1

•  $69B+TAMType2diabetes(90%ofallpeoplewithdiabetes)

•  $50B+TAMPre-diabetes—approximately3xpopulation

•  $60B+TAMWearableHealth-Techmarket:lowcarb/weightloss/fitness

U.S.CGMMarketOverview2•  U.S.hasthelargestnumberofCGMusers

globally(630kin2018)Only2.6%of25MUSdiagnoseddiabeticsusedCGMin2018

•  U.S.annualCGMusageincreasedby117%in201830%ofU.S.Type1peoplewithdiabetesuseCGM

•  3%ofU.S.Type2insulinusersuseCGM

CGMusageamongstnon-insulindiabeticsnegligible

•  U.S.has84MPeoplewithPre-diabetes

Continuous glucose monitoring (CGM): TAM

Understanding the opportunity

1&2PiperJaffrayCompanyNoteDXCMSep52018 14NASDAQ:NMRD

Current Product Pipeline

NASDAQ:NMRD 15

Product KeyFeatures Market

SugarBEAT®GenII •  Includepediatriccover•  Improvedaccuracy(MARD)•  Longerpatchweartime•  IncludeGestationaluse

•  TypeIIDiabetics•  Pre-Diabetics•  WearableHealth-Tech•  Pregnancy

ContinuousLactateMonitoring

•  World’sonlynon-invasiveskinpatchforcontinuouslactatemonitoring

•  Determinesappropriatetrainingintensitylevelsandmonitorsprogression

•  Athletes•  Fitness•  WearableHealth-Tech

marketexpectedtobeworth$60B+by20231

1JuniperResearchDigitalHealthReportJan142019

Future Product Pipeline

16

Product Uses Diagnostics

AlcoholMonitoring Supportpersonalhealthgoals,andprovidewarningspriortodriving,andprovidephysicianswithindividualdrinkinghabits

Preventionofprogressiontoalcoholrelateddiseases.

ProstaglandinMonitoring Screeningforinflammatoryirritantsinformulationsduringdrugandcosmeticdevelopment

Inflammation

LactateMonitoring Lactatemonitoringinintensivecare AnaerobicMetabolism

DrugMonitoring Monitoringtheimpactofdrugtreatmentfortreatment-regimencalibrationandpharmacokinetics

TreatmentRegimenOptimization

ContinuousTemperaturemonitoring

Temperaturemonitoringformonitoringviralinfections,andlowerlimbbloodcirculation

Viralinfectionsandtissuenecrosis

NASDAQ:NMRD

The Management Team Dr.FazChowdhury

ChiefExecutiveOfficer

Dr.ChowdhuryhasservedasCEOandchairoftheboardofNemauraMedicalsinceformationinDecember2013.Heissoleinventoronmorethan100grantedandpendingpatentsacrossover20technologyplatformswithinthemedicaldeviceandpharmaceuticalsectors.Hehas20yearsexperienceandtrackrecordtakingproductsfromconcepttoapproval,andhasbeenpivotalinthecompany’stechnicalandstrategicdevelopment.HehasauthoredTextbookChaptersonNano-biosciencesforWileyandElsevier,andservesontheBoardofMedilinkEastMidlands,UK.Dr.ChowdhuryholdsaMastersinMicrosystemsandNanotechnologyfromCranfieldUniversity,UK,andDoctoratefromtheUniversityofOxfordonnano-medicineanddrugdelivery.

ChrisAveryVicePresident,

GlobalBusinessOperationsMr.Averyhas35years’experienceindiabetes,gainingvastexperienceinglucosemonitoringandinsulindeliverymarkets.Heco-foundedaUKdiabetesdistributorshipin2000andservedasUKManagingDirectorandEuropeanDirectorlateracquiredbyNipro.Todatehehassuccessfullylaunchedover20glucosesystemseitherdirectorwithdistributorsandnegotiatedpartnershipsanddistributiondealswithpharmaceutical&medtechcompaniesacrossEuropeandotherinternationalmarkets.In2016hejoinedNemauraMedical’sEuropeanJVpartner,DallasBurstonEthitronixasSVPGlobalBusinessDevelopment,andworkedcloselywithDr.ChowduryuntiljoiningNemauraMedicalinJune2019.

Dr.FredSchaebsdauVicePresident,

Strategy&StrategicAlliancesDr.Schaebsdauhasover15yearsofexecutivelevelexperienceintheCGM,BloodGlucoseMonitoring(BGM)andinsulindeliveryindustries,whichstartedin2004duringhistenurewithAbboqDiabetesCare,wherehewasamemberoftheM&Aandpost-mergerintegrationteamsresponsiblefortheacquisitionofTheraSenseanditsFreeStyleNavigatorCGM.FromSeptember2016untilJanuary2019,hewastheGeneralManagerofDexcomGermany,whichduringhisleadershipbecamethefastestgrowingorganizationinDexcom’shistoryachievingtripledigitrevenueandnewpatientgrowtheveryyear.

17NASDAQ:NMRD

SugarBEAT® Clinical Data •  CompletedclinicalstudiesforFDAPMAsubmission

•  TheclinicalstudiesusedweresplitbetweenType1andType2diabetics

•  Consistedof75patientsover225patientdays

•  Generatedover12,000paireddatapoints,withbloodsamplestakenviacatheterevery15minutesovera12-hourperiodforthreenon-consecutivedaysforeachpatient

•  Studydesignwasbasedontwopreviouspre-submeetingsNemauraheldwiththeFDA

•  TheclinicalstudyresultsindicatedaMARD(MeanAbsoluteRelativeDeviation)of12.50%(withalowerfiguredenotinggreateraccuracy),usingasinglepointfingerstickcalibration,and10.75%with2fingerprickcalibrations

•  Nodevice-relatedadverseeventswerenotedNASDAQ:NMRD

18

Manufacturing •  Transmitterdeviceandchargingstation

•  AllmanufacturedintheUKandcanbereadilyscaledtobyaddingmultiplelinestowhatisalinearoperation.

•  Disposableskinadhesiveandancillarydisposableparts•  AllmanufacturedintheUKandcanbereadilyscaledtomillionsofunitspermonth.

•  Disposabledailysensor•  AllmanufacturedintheUKandcanbereadilyscaledtomillionsofunitspermonth,byaddingmultiplelinestowhatisalinearoperation.

•  Manufacturingscale

•  CurrentscalewillallowustolaunchintheUK,IrelandandGermany.

•  Futuremanufacturingwillbeoutsourcedtovariouslowcostregionsforthenon-specializedparts,butsensorproductiontoremaininUK.

NASDAQ:NMRD 19

Intellectual Property BuildinganextensiveintellectualpropertyportfoliotopositiontheCompanytobecomealeaderinthenon-invasiveCGMspace

TheCompanyhasoverthirtypatents(~70%approvedand~30%pending)spanningthefollowingpatentfamilies:

1.  Sensorrelated2.  AlgorithmandmethodsofusingtheCGMdata

3.  Devices&methodstoenhanceglucosesensing

4.  Methodstoenhanceglucosesensing

5.  Devicesandmethodstoextractglucose

TheCompanyanticipatesfilingmultipleadditionalpatentsoverthecourseofthenext18monthsbasedonongoingfindingsandimprovements.

20NASDAQ:NMRD

Summary •  NemauraMedicalaimstodominatetheglobaldiabetesmarketsforputtingType2diabetesintoremission,usingtheSugarBEAT®deviceanddigitalhealthcareplatform.

•  Within5yearsthecompanyaimstoleadinthewearablesmarketandself-managementofmedicalconditionswithitspipelineproductsofsensorsanddigitalhealthcareplatformusingAI.

•  Thecompanyhasthepotentialtodisruptthemulti-Billiondollarglucosetrendinganddiabetesmanagementspacetargeting$179B+Globalopportunity:

•  PlannedLaunchofSugarBEAT®inkeyglobalterritoriesby2020andaimingfor1millionusersby2021,and3millionusersby2023

•  Digitalhealthsectorcomprising$69B+Type2diabeticmarket&$50B+pre-diabeticmarket

•  AimingtobuildontheLivongomodel,butusingthecompany’sproprietaryuniquedeviceplatform,henceamoresubstantialinvestmentproposition

•  Wearablehealth-techsectorcomprising$60B+weightloss&wellnessmarkets•  USapprovalandlaunchanticipatedbyendof2020•  CEMarkApproved;UK&IrelandcommerciallaunchexpectedinQ12020,followedby

Germany•  Lowestpriced,highrecurringmarginmodel,withlowestCOGSperCGMpatchinthe

industry

•  GrowingIPportfoliowithover30issued&pendingpatents•  Launchingcontinuouslactatemonitoring(CLM)nearterm,targeting$60B+wearable

techmarket•  Pipelineoffourotherproductsincludingnon-invasivecontinuousalcoholmonitoring

(CAM)

•  Provenmanagementteamwithsuccessfultrackrecords•  Cleancapitalstructure

NASDAQ:NMRD 21